[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Provectus Biopharms (PVCT)

Provectus Biopharms (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Provectus Biopharms 800 S Gay Street Suite 1610 KNOXVILLE TN 37929 USA

www.provectusbio.com Employees: 6 P: 866-594-5999

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. The company's product portfolio consists of PV-10 Melanoma, PH-10 Psoriasis, PH-10 Atopic Dermatitis, PV-10 Breast Cancer, PV-10 Liver Metastasis and PV-10 Mechanism of Action which are in clinical trials. Provectus Biopharmaceuticals Inc., formerly known as Provectus Pharmaceuticals, Inc., is based in Knoxville, Tennessee.

Key Statistics

Overview:

Market Capitalization, $K 26,520
Enterprise Value, $K 26,320
Shares Outstanding, K 420,280
Float, K 366,484
% Float 87.20%
Short Interest, K 19
Short Float 0.00%
Days to Cover 1.00
Short Volume Ratio 0.60
% of Insider Shareholders 12.80%
% of Institutional Shareholders 0.05%

Financials:

Annual Sales, $ 340 K
Annual Net Income, $ -5,430 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -1,290 K
EBIT, $ -5,450 K
EBITDA, $ -5,440 K

Growth:

1-Year Return -12.47%
3-Year Return -43.74%
5-Year Return -3.44%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 50.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.00 on 05/14/26
Next Earnings Date 08/13/26
Earnings Per Share ttm 0.00
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

PVCT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -923.24%
Profit Margin % -1,597.06%
Debt/Equity -0.22
Price/Sales 78.80
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.02
Interest Coverage -25.24
60-Month Beta 0.85
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.